2022 Revenues ($USD) : $16,218,100,000.00
2022 R&D spend : $662,200,000.00
2022 Number of Employees : 37000
Fiscal Year End : 12/31/22
Leader : CEO Scott Smith (effective April 2023)

Viatris reported robust financial results for the fourth quarter and full year 2022, meeting its adjusted guidance range after accounting for the impact of its biosimilars transaction with Biocon Biologics and acquired IPR&D. The company's strong performance in the developed and emerging markets, along with its brands and complex generics sectors, contributed to its solid results. The company successfully paid down approximately $3.3 billion of debt in 2022 and increased the return of capital to shareholders with the completion of $250 million in share repurchases. The company's board of directors also approved a 2023 dividend policy of 48¢ per share, with a first-quarter dividend of 12¢ per share. Its 2023 financial guidance reflects revenue growth over 2022, excluding the full-year impact of biosimilars. —BB